Skip to content

ICLR changes

Pick any two versions below to diff them.

View the full Nov 21, 2026 version
Price
$200.51 → $186.71(−6.9%)
Discount category
Pricey → Close to intrinsic value
Thesis
The price of ICON depends on whether investors trust its reported numbers removed: again and added: again, whether its strong bookings turn into revenue removed: growth. added: growth and whether its profit margin recovers. In February 2026 ICON said that its Audit Committee was investigating its accounting practices, and in April 2026 the investigation found that revenue was overstated in 2023 and 2024. ICON restated those years and the first nine months of 2025, reported material weaknesses and filed its 2025 Form 20-F late, on May 27, 2026. added: During the same review, ICON changed its policy on cancellations. This cut its reported backlog by $3.9 billion, from about $25.0 billion to $21.1 billion at October 1, 2025, which is about 16% less. The cut changed the way ICON counts backlog, and ICON said that it did not change how awards enter backlog. Backlog was $24.5 billion at September 30, 2026. Revenue fell 2.9% in Q3 2026 and adjusted diluted earnings per share fell to $2.66 from $3.20, but net business wins were $3,150 million, a book-to-bill of 1.56 times. added: Profit margin is the second part of the case. ICON's adjusted EBITDA margin was 20.4% in 2023 and in 2024 (restated), 18.6% in 2025 and 16.6% in Q3 2026. Revenue is almost flat, so a return of the margin toward 20% would raise earnings more than revenue growth would. Management points to better business mix, cost discipline and its AI-enabled digital platform as the ways to do this. Peers show the size of the gap. In Q3 2026, IQVIA reported an adjusted EBITDA margin of 23.3% ($1,032 million on revenue of $4,428 million) and revenue growth of 8.0%. Medpace reported an EBITDA margin of 24.0% and revenue growth of 8.5%. Charles River reported a non-GAAP operating margin of 23.0% and revenue growth of 4.7% on an organic basis, which is a different measure of profit. ICON reported 16.6% and a revenue decline of 2.9%. Each company defines its own measures, so compare the direction and not the last digit. For the price to hold or rise, removed: four added: five things must be true. ICON must fix its material weaknesses with no new restatement. The backlog of $24.5 billion must turn into revenue growth in 2027 with few cancellations. added: The adjusted EBITDA margin must keep rising from 16.6%. Pharmaceutical and biotechnology customers must keep their research and development budgets. The securities class actions must not lead to large costs. The added: bull case is that AI tools make drug discovery faster, so more drug candidates reach clinical trials, and ICON can run those trials with its own AI tools at lower cost. This is an argument, not a fact: no ICON report shows it in revenue yet. The Q4 2026 report, expected in February 2027, with its 2027 guidance, is the next test.
Checkpoints
Feb 17, 2027 (estimate): Q4 2026 results and 2027 guidance. Pending. Watch: Revenue for 2026 is in the range of $8,100 million to $8,200 removed: million and added: million, the 2027 guidance shows revenue removed: growth, added: growth and added: the Q4 2026 adjusted EBITDA margin is above the 16.6% of Q3 2026, and this passes; revenue below the removed: range or added: range, a guided decline added: or a lower margin fails. Apr 2027 (estimate): 2026 annual report on Form 20-F. Pending. Watch: ICON files its 2026 Form 20-F on time with no new restatement and reports progress on its material weaknesses, and this passes; a late filing or a new restatement fails.
Recent events
Oct 27, 2026: ICON reported Q3 2026 results. Revenue fell 2.9% to $2,024.8 million, adjusted EBITDA was $336.9 million and adjusted diluted earnings per share were $2.66. Net business wins were $3,150 million and backlog was $24.5 billion. ICON updated its 2026 guidance to revenue of $8,100 million to $8,200 million and adjusted diluted earnings per share of $10.35 to $10.65. The board increased the total share repurchase authorization to $750.0 million. Aug 13, 2026: ICON issued $2.15 billion of senior unsecured notes due 2029, 2031 and 2036. It used the proceeds to repay its $900 million term loan, redeem its $750 million of notes due May 2027 and repay its $500 million bridge facility. Jun 26, 2026: The lead plaintiffs in the securities class actions against ICON filed a second amended complaint, which adds the current Chief Financial Officer and a former employee as defendants. May 27, 2026: ICON filed its 2025 annual report on Form 20-F with restated results for 2023, 2024 and the first nine months of 2025. Before this, Nasdaq had sent a notice that ICON did not comply with its rule on timely filing. added: In its Q4 2025 release on the same day, ICON said that a new policy on cancellations cut its reported backlog by $3.9 billion to $21.1 billion at October 1, 2025, and that its adjusted EBITDA margin was 18.6% for 2025 and 15.5% for Q4 2025. Apr 29, 2026: The Audit Committee completed its investigation. It found that revenue was overstated in 2023 and 2024 by less than 2% each year, and ICON said that it will restate those years and the first nine months of 2025. Feb 12, 2026: ICON announced an investigation by its Audit Committee into its accounting practices, which started in late October 2025, and withdrew its 2025 guidance.